Grace Therapeutics, Inc. Common Stock (GRCE) Stock Price

GRCEStock

$1.89−41.12%52W

Market Cap$39.76M

P/E—

PEG Ratio—

Div yield—

Beta0.37

GRCE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-65.75%

Price vs S&P 500 (4W)-8.67%

VGM Score40.32

Book Value / Share (Quarterly)$2.96

P/TBV (Annual)3.15x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.63

Price vs S&P 500 (YTD)-57.30%

Gross Margin (TTM)65.00%

Net Profit Margin (TTM)-4435.00%

EPS (TTM)$-1.18

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-1.18

EPS (Annual)$-1.35

ROI (Annual)-20.82%

Gross Margin (Annual)60.00%

Net Profit Margin (5Y Avg)-5595.44%

Cash / Share (Quarterly)$0.85

ROA (Last FY)-17.53%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-64.77%

Operating Margin (TTM)-2130.00%

Cash Flow / Share (Annual)$-0.55

P/B Ratio0.82x

P/B Ratio (Quarterly)0.77x

Net Income / Employee (Annual)$-401,700

Net Interest Coverage (TTM)-7.01x

ROA (TTM)-32.12%

EPS Incl Extra (Annual)$-1.35

Current Ratio (Annual)8.10x

Quick Ratio (Quarterly)11.02x

3-Month Avg Trading Volume0.19M

52-Week Price Return-41.12%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.27

P/S Ratio (Annual)198.79x

Asset Turnover (Annual)0.00x

52-Week High$5.18

Operating Margin (5Y Avg)-5314.69%

EPS Excl Extra (Annual)$-1.35

26-Week Price Return-55.84%

Quick Ratio (Annual)7.92x

13-Week Price Return-23.48%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.47x

Enterprise Value$26.00M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.40x

Pretax Margin (Annual)-9840.00%

Cash / Share (Annual)$1.06

3-Month Return Std Dev37.43%

Gross Margin (5Y Avg)67.56%

Net Income / Employee (TTM)$-631,900

ROE (Last FY)-20.82%

Net Interest Coverage (Annual)-5.12x

EPS Basic Excl Extra (Annual)$-1.35

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.18

Receivables Turnover (Annual)1.60x

ROI (TTM)-33.73%

P/S Ratio (TTM)198.79x

Pretax Margin (5Y Avg)-5595.44%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.42

Price vs S&P 500 (52W)-56.65%

Year-to-Date Return-45.38%

5-Day Price Return-6.44%

EPS Normalized (Annual)$-1.35

ROA (5Y Avg)-44.34%

Net Profit Margin (Annual)-9840.00%

Month-to-Date Return-12.09%

EBITD / Share (Annual)$-1.34

Operating Margin (Annual)-8210.00%

LT Debt / Equity (Annual)0.20x

ROI (5Y Avg)-64.77%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-1.18

P/TBV (Quarterly)1.79x

P/B Ratio (Annual)1.12x

Inventory Turnover (TTM)1.00x

Pretax Margin (TTM)-4435.00%

Book Value / Share (Annual)$3.99

Price vs S&P 500 (13W)-26.17%

Beta0.37x

Revenue / Share (TTM)$0.00

ROE (TTM)-33.73%

52-Week Low$1.79

mGradeC

vgmGradeC

GRCE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.18	-$0.18	+0.98%(+$0.00)
Q1 2026	Jun 18, 2026	-$0.20	-$0.08	+58.94%(+$0.12)
Q4 2025	Feb 12, 2026	-$0.39	-$0.19	+51.59%(+$0.20)
Q3 2025	Nov 13, 2025	-$0.34	-$0.08	+75.56%(+$0.26)
Q2 2025	Aug 12, 2025	-$0.31	-$0.29	+5.99%(+$0.02)

GRCE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GRCEGrace Therapeutics, Inc. Common Stock	—	—	C	198.8x	—	65.0%	—	$1.89
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Grace Therapeutics, Inc. Common Stock

Grace Therapeutics is a specialty pharmaceutical company developing drug delivery technologies for rare and orphan diseases. Its lead program, GTx-104, is a novel injectable nimodipine formulation in late-stage development for aneurysmal subarachnoid hemorrhage. The company's pipeline includes additional candidates targeting ataxia-telangiectasia, postherpetic neuralgia, and other rare disease indications.

GRCE Insider Transactions

BuyOct 5, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 60,490Value: $123,819
BuySep 29, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 7,849Value: $16,404
BuySep 23, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 15,089Value: $31,687
BuySep 9, 2026
KOHLI PRASHANT
Chief Executive Officer
Shares: 100,000Value: $214,000
BuySep 9, 2026
OPALEYE MANAGEMENT, INC.
Beneficial Owner of more than 10% of a Class of Security
Shares: 15,229Value: $31,896

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

VGASVerde Clean Fuels, Inc. Class A Common StockIndustrial Chemicals
INMBINmune Bio Inc. Common stockBiological Products
BYAHPark Ha Biological Technology Co., Ltd. Ordinary SharesSoap & Detergents
TILInstil Bio, Inc. Common StockBiological Products
BSEMBioStem Technologies, Inc. Common StockBiological Products
EXOZeXoZymes Inc. Common StockBiological Products
AXILAXIL Brands, Inc.Cosmetics & Toiletries
BTMDBiote Corp. Class A Common StockPharmaceutical Preparations

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$1.79

High$5.18